Novo Nordisk Shares Drop After Late-Stage Trial Failure
Novo Nordisk (NVO) saw its shares fall nearly 8% in premarket trading after announcing the failure of a Phase 3 trial for ziltivekimab, an anti-inflammatory drug candidate. The setback is expected to impact the company's financial outlook and development pipeline. The failed clinical trial highlights challenges in bringing new therapies to market and could delay or reduce potential revenue from this promising compound. Investors reacted negatively due to concerns over Novo Nordisk’s ability to maintain its growth trajectory.
Tickers: $NVO
Topics: clinical trial failure drug development stock price movement